Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Richmond Pharmacology's Volunteer Database Exceeds 100,000 Volunteer Registration Records

14
April 2010

View Articles

Richmond Pharmacology (RPL) will be attending this month's 22nd Annual DIA EuroMeeting, taking place 8-10 March 2010 in Monaco.

1
March 2010

View Articles

Richmond Pharmacology is proud to announce that it will be hosting the AHPPI Winter Meeting early next month.

7
December 2009

View Articles

9th April 2009

9
April 2009

View Articles

Richmond Pharmacology, the 1st Early Phase CRO to receive MHRA Standard and Supplementary Accreditation for 2 hospital based Clinical Trial Centres.

17
October 2008

View Articles

Richmond Pharmacology take part in the MS Society Wheel and Walk: A great Success for all!

15
July 2008

View Articles

Latest news

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Von Willebrand Disease Trial – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read more

Events

Swiss Biotech Day 2025

5–6 May 2025
Richmond Pharmacology is pleased to confirm our participation at Swiss Biotech Day 2025
View event